TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02346383

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: preset program
Description: Change to different present program using epidural and peripheral lead to cover pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: preset program
Description: Change to different present program using epidural and peripheral lead to cover pain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: preset program
Description: Change to different present program using epidural and peripheral lead to cover pain
Study: NCT04377165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gamification
Description: This will provide the user with the newsfeed function and the addition of a gamification function

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newsfeed function
Description: This will provide the user with reliable accurate information on the pandemic.
Study: NCT01114854

Intervention type: DRUG
Group type: OTHER
Intervention: Topiramate IR

Intervention type: DRUG
Group type: OTHER
Intervention: Topiramate ER
Study: NCT04112004

Intervention type: OTHER
Intervention: Collecting sodium reports and outcome measures
Study: NCT03409276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLA-SE adjuvant
Description: Administered by intramuscular injection in the deltoid.
Study: NCT02794441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral solution
Study: NCT04222348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 850-2550 mg every 24h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850-2550 mg every 24h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Detemir
Description: Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Detemir
Description: Insulin detemir associated or not with rapid insulin analogue (aspart) according to individual glycemic controls.
Study: NCT01367873

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, matching number of placebo capsule(s) with active arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-3196
Description: Oral, capsule(s)
Study: NCT02559674

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
Study: NCT00114868

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin A
Study: NCT00540150

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)
Description: We treat each patient with mite-allergen following the two different protocols.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)
Description: We treat each patient with mite-allergen following the two different protocols.
Study: NCT03220269

Intervention type: OTHER
Intervention: Out-of-hospital cardiac arrest (OHCA)
Description: Data collection

Intervention type: OTHER
Intervention: In-hospital cardiac arrest (IHCA)
Description: Data collection
Study: NCT00114868

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Study: NCT01787617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Plus Resistance Training Group
Description: Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
Study: NCT02676167

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PrEP Intervention
Study: NCT03894865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procedure1
Description: The students will be asked to bend forward with his knees straight, feet together and hands freely and loosely hanged. if there was scoliosis the rib cage rotated and a hump appeared. Positive test indicated the presence of a rib hump and negative if there was any hump appeared

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procedure1
Description: The students will be asked to bend forward with his knees straight, feet together and hands freely and loosely hanged. if there was scoliosis the rib cage rotated and a hump appeared. Positive test indicated the presence of a rib hump and negative if there was any hump appeared

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procedure2
Description: Measurement of the angle of trunk rotation (ATR) by using a scoliometer HD smartphone application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procedure2
Description: Measurement of the angle of trunk rotation (ATR) by using a scoliometer HD smartphone application.
Study: NCT00907153

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 300 mcg by mouth once daily for 12 weeks
Study: NCT02788305

Intervention type: DRUG
Intervention: Misoprostol
Description: Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups

Intervention type: DRUG
Intervention: Misoprostol
Description: Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
Study: NCT02339506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosyntropin
Description: Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
Study: NCT00907153

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth once daily for 12 weeks
Study: NCT02883114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06648671
Description: Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
Study: NCT02201069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coaching
Study: NCT01043666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine ER
Description: oral
Study: NCT00272168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maryland Program for Vocational Effectiveness
Description: psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Treatment for SMI
Description: Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
Study: NCT02367911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 122-0551 Foam
Description: 122-0551 Foam applied twice daily to treat psoriasis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle Foam applied twice daily to treat psoriasis
Study: NCT04068753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib: 200 mg, oral, once daily, days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dostarlimab
Description: dostarlimab: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks for up to two years
Study: NCT02730494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lcr Regenerans® vaginal capsules

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lcr Regenerans® vaginal tablet
Study: NCT00976001

Intervention type: OTHER
Group type: OTHER
Intervention: Information, further rehabilitation, additional drugs to prevent recurrent stroke
Study: NCT02730494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lcr Regenerans® vaginal tablet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lcr Regenerans® vaginal tablet
Study: NCT04966468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The Lenovo Mirage Solo Headset will be kept at home by the patient for the duration of the study (4 days). The VR headset will be equipped with 10 non-interactive videos and a short interactive game. The videos and the game are characterized by relaxing scenarios. The game will require the active interaction of the patient. At the end of the observational period, the investigator will download the usage data to detect information about the patient's use. Before and after each use of the VR headset, the patient will be asked to fulfil the Edmonton Symptom Assessment Scale (ESAS). On T0, the patient will be asked to wear a wearable device, the Empatica E4 wristband measuring physiological parameters. On day T1, the patient will return the VR headset and the wristband to the investigator and will fulfil again the HADS and BPI questionnaires.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The investigator will illustrate to the patient how to use the tablet for watching videos, suggesting using it especially in moments of psycho-physical discomfort. The tablet will be given to the patient for the duration of the study (four days). The tablet will be equipped with 10 non-interactive 2D videos characterized by relaxing settings with natural or artistic scenarios, giving a passive use to the patient. Before and after each use of the tablet, patient has to fullfil the ESAS digitally inserted into the tablet. Patient can answer by selecting the answer on the touchscreen. Without filling the scale, the patient will not be able to access the videos inserted in the tablet. On day T1, patient will return the tablet to the investigator and fill out the HADS and BPI questionnaires.
Study: NCT00581230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with RAMP
Description: inflatable positioning ramp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy without RAMP
Description: Laryngoscopy without RAMP
Study: NCT01353313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days
Study: NCT02780388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIB4920
Description: Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
Study: NCT00609245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
Study: NCT02780388

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
Study: NCT00976001

Intervention type: OTHER
Group type: OTHER
Intervention: As the general practitioner wants to do
Study: NCT01543035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stop statin and switch to an antiretroviral drug with less impact on lipid metabolism
Description: Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
Study: NCT01448343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid management system 2000 (FMS)
Description: The FMS has an integrated large volume (about 3000 ml) reservoir and delivers a blood mixture (4 unit RBC, 4 unit FFP and 800 ml normal saline) put in the reservoir at a maximum rate of 750 ml/min.
Study: NCT03272633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Receive IHC
Study: NCT03522779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.
Study: NCT04433481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: T. Dabigatran 150 mg twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02961920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IE ratio 1:1
Description: Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IE ratio 1:2
Description: Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
Study: NCT01169090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-0403
Description: SK-0403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-0403
Description: SK-0403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-0403
Description: SK-0403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-0403
Description: SK-0403

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin
Study: NCT00568269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open repair
Description: Open repair is according to the Lichtenstein technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Description: The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
Study: NCT00974493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.~Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.
Study: NCT03272633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Receive IHC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Irradiated Allogeneic Cells
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Irradiated Allogeneic Cells
Description: Correlative studies
Study: NCT01996254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study: NCT01436058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
Study: NCT02088060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Cannabidiol
Description: Placebo cannabidiol capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cannabidiol
Description: Placebo cannabidiol capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Olanzapine
Description: Placebo olanzapine capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Olanzapine
Description: Placebo olanzapine capsules
Study: NCT01260220

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential Antral Ablation
Description: The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Segmental Antral ablation
Description: If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
Study: NCT03694249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Sodium
Description: Given by mouth

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given by mouth
Study: NCT02746497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally.